Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

57.59 +2.07 (+3.72%)
Streaming Delayed Price Updated: 11:54 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
37 38 Next >
News headline image
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data ↗
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
News headline image
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche ↗
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
News headline image
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)... 
Via TheNewswire.com
Topics ETFs Economy Stocks
News headline image
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
News headline image
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗
 
Via Benzinga
News headline image
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
From Spark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
From Genentech
Via Business Wire
News headline image
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12 ↗
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
News headline image
After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗
 
Via Benzinga
News headline image
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
From Genentech
Via Business Wire
News headline image
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
From Genentech
Via Business Wire
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
News headline image
3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗
These companies have long runways of growth ahead 
Via The Motley Fool
News headline image
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗
 
Via Benzinga
News headline image
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
News headline image
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges ↗
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
News headline image
This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends ↗
Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel... 
Via Benzinga
News headline image
Daily Stock Analysis: Roche Holding ↗
By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗
 
Via Benzinga
News headline image
FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗
 
Via Benzinga
News headline image
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗
 
Via Benzinga
News headline image
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗
 
Via Benzinga
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones... 
Via TheNewswire.com
Topics ETFs Stocks
News headline image
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer ↗
 
Via Benzinga
News headline image
Why Is Cassava Sciences (SAVA) Stock Up Today? ↗
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
News headline image
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads ↗
The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads. 
Via Investor's Business Daily
News headline image
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗
 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.